肝癌/美巴龙。西南肿瘤协作组的一项研究。
Hepatoma/merbarone. A Southwest Oncology Group study.
作者信息
Poplin E A, Tangen C M, Harvey W H, Macdonald J S
机构信息
Wayne State University Medical Center, Detroit, MI, USA.
出版信息
Invest New Drugs. 1994;12(4):337-40. doi: 10.1007/BF00873051.
PMID:7775137
Abstract
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.
摘要
16例符合条件的既往未接受过治疗的肝细胞癌患者，每21天连续5天接受每日1000mg/m²的美巴龙治疗。未获得对治疗的完全或部分缓解。7例患者出现4级粒细胞减少。1例患者死于肾衰竭。该剂量和疗程的美巴龙治疗肝细胞癌无效。
Zotero 插件